Molecular mechanism underlines heparin-induced thrombocytopenia and thrombosis

Progress in Molecular Biology and Translational Science

Volumn 93, Issue C, 2010, Pages 395-421

  Qian, Yi ^a   Pan, Jing ^a   Zhou, Xiaodong ^a   Weiser, Peter ^a   Lu, Hong ^a   Zhang, Lijuan ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

C1 inhibitor; Factor XII; Glycosaminoglycan; Heparin induced thrombocytopenia; Kallikrein; Kininogen; TAFI; Thrombin

Indexed keywords

ANTICOAGULANT AGENT; HEPARIN;

ANIMAL; CHEMICALLY INDUCED DISORDER; HUMAN; IMMUNOLOGY; REVIEW; THROMBOCYTOPENIA; THROMBOSIS;

ANIMALS; ANTICOAGULANTS; HEPARIN; HUMANS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 77958183682     PISSN: 18771173     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1877-1173(10)93017-2     Document Type: Chapter

References (50)

1. T.E. Warkentin, M.N. Levine, J. Hirsh, P. Horsewood, R.S. Roberts, and M. Gent Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin N Engl J Med 332 1995 1330 1335
2. M.E. Comunale, and E.M. Van Cott Heparin-induced thrombocytopenia Int Anesthesiol Clin 42 2004 27 43
3. A. Greinacher, and T.E. Warkentin Contaminated heparin N Engl J Med 359 2008 1291 1292 (author reply 1293)
4. B. Tardy-Poncet, M. Piot, C. Chapelle, G. France, L. Campos, and O. Garraud Thrombin generation and heparin-induced thrombocytopenia (HIT) J Thromb Haemost 7 2009 1474 1481
5. P.M. Newman, and B.H. Chong Heparin-induced thrombocytopenia: new evidence for the dynamic binding of purified anti-PF4-heparin antibodies to platelets and the resultant platelet activation Blood 96 2000 182 187
6. D.B. Cines, L. Rauova, G. Arepally, M.P. Reilly, S.E. McKenzie, and B.S. Sachais Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly J Clin Apher 22 2007 31 36
7. S.R. Coughlin Protease-activated receptors and platelet function Thromb Haemost 82 1999 353 356
8. J.G. Kelton, and T.E. Warkentin Heparin-induced thrombocytopenia: a historical perspective Blood 112 2008 2607 2616
9. C. Adiguzel, V. Bansal, E. Litinas, J. Cunanan, O. Iqbal, and K. Nelson Increased prevalence of antiheparin platelet factor 4 antibodies in patients may be due to contaminated heparin Clin Appl Thromb Hemost 15 2009 145 151
10. T.K. Kishimoto, K. Viswanathan, T. Ganguly, S. Elankumaran, S. Smith, and K. Pelzer Contaminated heparin associated with adverse clinical events and activation of the contact system N Engl J Med 358 2008 2457 2467 (Pubitemid 351793019)
11. D.B. Blossom, A.J. Kallen, P.R. Patel, A. Elward, L. Robinson, and G. Gao Outbreak of adverse reactions associated with contaminated heparin N Engl J Med 359 2008 2674 2684
12. B.A. Waaler Contact activation in the intrinsic blood clotting system; studies on a plasma product formed on contact with glass and similar surfaces Scand J Clin Lab Invest 11 1959 1 133
13. R.W. Colman Contact activation (kallikrein-kinin) pathway: multiple physiologic and pathophysiologic activities R.W. Colman, Hemostasis and thrombosis 2006 Lippincott Williams & Wilkins Philadelphia 107 130
14. A.H. Schmaier Assembly, activation, and physiologic influence of the plasma kallikrein/kinin system Int Immunopharmacol 8 2008 161 165
15. C.W. Gilstad Anaphylactic transfusion reactions Curr Opin Hematol 10 2003 419 423
16. M.J. Meth, and H.I. Maibach Current understanding of contrast media reactions and implications for clinical management Drug Saf 29 2006 133 141
17. A.H. Schmaier, and K.R. McCrae The plasma kallikreinkinin system: its evolution from contact activation J Thromb Haemost 5 2007 2323 2329
18. T. Shimada, H. Kato, S. Iwanaga, M. Iwamori, and Y. Nagai Activation of factor XII and prekallikrein with cholesterol sulfate Thromb Res 38 1985 21 31
19. T. Shimada, T. Sugo, H. Kato, K. Yoshida, and S. Iwanaga Activation of factor XII and prekallikrein with polysaccharide sulfates and sulfatides: comparison with kaolin-mediated activation J Biochem 97 1985 429 439
20. Y. Hojima, C.G. Cochrane, R.C. Wiggins, K.F. Austen, and R.L. Stevens In vitro activation of the contact (Hageman factor) system of plasma by heparin and chondroitin sulfate E Blood 63 1984 1453 1459
21. C. Maas, J.W. Govers-Riemslag, B. Bouma, B. Schiks, B.P. Hazenberg, and H.M. Lokhorst Misfolded proteins activate Factor XII in humans, leading to kallikrein formation without initiating coagulation J Clin Invest 118 2008 3208 3218
22. F. van der Graaf, J.A. Koedam, and B.N. Bouma Inactivation of kallikrein in human plasma J Clin Invest 71 1983 149 158
23. J. Pan, Y. Qian, X. Zhou, A. Pazandak, S.B. Frazier, and P. Weiser Identification of chemically sulfated/desulfated glycosaminoglycans in contaminated heparins and development of a simple assay for the detection of most contaminants in heparin Glycobiol Insight 2 2010 1 12
24. J. Pan, Y. Qi, X. Zhou, H. Lu, E. Ramacciotti, and L. Zhang Chemically oversulfated glycosaminoglycans are potent modulators of contact system activation and different cell signaling pathways J Biol Chem 2010 10.1074/jbc.M109.063735
25. J. Pan, Y. Qi, X. Zhou, H. Lu, E. Ramacciotti, and L. Zhang Chemically oversulfated glycosaminoglycans are potent modulators of contact system activation and different cell signaling pathways J Biol Chem 2010 doi: 10.1074/jbc.M109.063735
26. J. Szebeni, C.R. Alving, L. Rosivall, R. Bunger, L. Baranyi, and P. Bedocs Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles J Liposome Res 17 2007 107 117
27. A. Radomski, P. Jurasz, D. Alonso-Escolano, M. Drews, M. Morandi, and T. Malinski Nanoparticle-induced platelet aggregation and vascular thrombosis Br J Pharmacol 146 2005 882 893
28. D. Simberg, W.M. Zhang, S. Merkulov, K. McCrae, J.H. Park, and M.J. Sailor Contact activation of kallikreinkinin system by superparamagnetic iron oxide nanoparticles in vitro and in vivo J Control Release 140 2009 301 305
29. N.S. Jenny, R.L. Lundblad, and K.G. Mann Thrombin R.W. Colman, Hemostasis and thrombosis 2006 Lippincott Williams & Wilkins Philadelphia 193 213
30. T.W. Stief Kallikrein activates prothrombin Clin Appl Thromb Hemost 14 2008 97 98
31. B.L. Zuraw, and J.G. Curd Demonstration of modified inactive first component of complement (C1) inhibitor in the plasmas of C1 inhibitor-deficient patients J Clin Invest 78 1986 567 575
32. R.W. Colman, J.V. White, S. Scovell, A. Stadnicki, and R.B. Sartor Kininogens are antithrombotic proteins in vivo Arterioscler Thromb Vasc Biol 19 1999 2245 2250
33. F.J. Meloni, and A.H. Schmaier Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation J Biol Chem 266 1991 6786 6794
34. U. Schulze-Topphoff, A. Prat, M. Bader, F. Zipp, and O. Aktas Roles of the kallikrein/kinin system in the adaptive immune system Int Immunopharmacol 8 2008 155 160
35. A. Ueno, and S. Oh-ishi Roles for the kallikreinkinin system in inflammatory exudation and pain: lessons from studies on kininogen-deficient rats J Pharmacol Sci 93 2003 1 20
36. R.W. Colman, A.W. Clowes, J.N. George, S.Z. Goldhaber, and V.J. Marder Overview of hemostasis R.W. Colman, Hemostasis and thrombosis 2006 Lippincott Williams & Wilkins Philadelphia 3 16
37. T. Orfeo, K.E. Brummel-Ziedins, M. Gissel, S. Butenas, and K.G. Mann The nature of the stable blood clot procoagulant activities J Biol Chem 283 2008 9776 9786
38. L.M. Asmis, I. Sulzer, M. Furlan, and B. Lammle Prekallikrein deficiency: the characteristic normalization of the severely prolonged aPTT following increased preincubation time is due to autoactivation of factor XII Thromb Res 105 2002 463 470
39. J. Amiral, A. Marfaing-Koka, M. Wolf, M.C. Alessi, B. Tardy, and C. Boyer-Neumann Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia Blood 88 1996 410 416
40. L. Zhang, D.L. Beeler, R. Lawrence, M. Lech, J. Liu, and J.C. Davis 6-O-sulfotransferase-1 represents a critical enzyme in the anticoagulant heparan sulfate biosynthetic pathway J Biol Chem 276 2001 42311 42321
41. A. Greinacher, M. Gopinadhan, J.U. Gunther, M.A. Omer-Adam, U. Strobel, and T.E. Warkentin Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies Arterioscler Thromb Vasc Biol 26 2006 2386 2393
42. T. Meyer, L. Robles-Carrillo, T. Robson, F. Langer, H. Desai, and M. Davila Bevacizumab immune complexes activate platelets and induce thrombosis in FCGR2A transgenic mice J Thromb Haemost 7 2009 171 181
43. W.L. Duvall Antithrombotic therapy Curr Mol Med 6 2006 603 619
44. S.A. Mousa Role of current and emerging antithrombotics in thrombosis and cancer Timely Top Med Cardiovasc Dis 10 2006 E19
45. M. Bartnik, A. Norhammar, and L. Ryden Hyperglycaemia and cardiovascular disease J Intern Med 262 2007 145 156
46. A. Grand'Maison, A.F. Charest, and W.H. Geerts Anticoagulant use in patients with chronic renal impairment Am J Cardiovasc Drugs 5 2005 291 305
47. J.J. Swigris, A. Fischer, J. Gillis, R.T. Meehan, and K.K. Brown Pulmonary and thrombotic manifestations of systemic lupus erythematosus Chest 133 2008 271 280
48. L.-A.M.D. Linkins, and T.M.D. Warkentin The approach to heparin-induced thrombocytopenia Semin Respir Crit Care Med 2008 066 074
49. E.S. Mullins, K.W. Kombrinck, K.E. Talmage, M.A. Shaw, D.P. Witte, and J.M. Ullman Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain Blood 113 2009 696 704
50. J. Pan, Y. Qian, X. Zhou, A. Pazandak, S.B. Frazier, and P. Weiser Oversulfated chondroitin sulfate is not the sole contaminant in heparin Nat Biotechnol 28 2010 203 207